Medicus Pharma Focuses on Pfizer-Licensed Cancer Drug CD228V, Cuts Costs in Q3

• Medicus Pharma is focusing on the Pfizer-licensed cancer drug CD228V.
• The company reported cost-cutting measures in Q3.
• The announcement was made during the Q3 2026 earnings call.
• The focus on CD228V is part of Medicus Pharma's strategic initiatives.
• Cost reductions were implemented to improve financial efficiency.